

WHAT IS CLAIMED IS:

Sub-B  
1. In a method of treating a condition in a host by administering an effective amount of a selective estrogen receptor modulator to the host to control and regulate estrogenic impact on specific tissues and organs, the improvement which comprises additionally administering an effective amount of an agent which exhibits progestogenic activity to the host.

2. The method of claim 1 wherein the selective estrogen receptor modulator is clomiphene.

3. The method of claim 1 wherein the selective estrogen receptor modulator is a benzothiophene.

4. The method of claim 1 wherein the additional agent is an antiprogestin which exhibits progestogenic activity.

5. The method of claim 4 wherein the antiprogestin is a progesterone receptor antagonist.

6. The method of claim 5 wherein the selective estrogen receptor modulator is clomiphene.

7. The method of claim 5 wherein the selective estrogen receptor modulator is a benzothiophene.

8. The method of claim 4 wherein the amount of antiprogestin is that sufficient to maintain the blood

estrogen concentration in the range of about 25 to 125 pg/ml.

9. The method of claim 8 wherein the amount of antiprogesterin is that sufficient to maintain the blood estrogen concentration in the range of about 60 to 90 pg/ml.

10. The method of claim 1 wherein the ~~additional~~ <sup>which exhibits progestogenic</sup> agent expresses both androgenic and progestogenic activity.

11. The method of claim 10 wherein the ~~additional~~ <sup>which exhibits progestogenic</sup> agent comprises the combination of an androgen and a progestin.

12. The method of claim 10 wherein the ~~additional~~ <sup>which exhibits</sup> agent is a single material which expresses both activities.

13. The method of claim 12 wherein the ~~additional~~ <sup>which exhibits progestogenic</sup> agent is danazol or levonorgestrel.

14. A kit comprising a plurality of tablets containing an effective amount of a selective estrogen receptor modulator and an effective amount of an agent which exhibits progestogenic activity.

15. The kit of claim 14 wherein the selective estrogen receptor modulator is clomiphene or a benzothiophene.

B 16. The kit of claim 14 wherein the agent is <sup>which exhibits progestogenic</sup> an antiprogestin. <sub>A</sub>

17. The kit of claim 16 wherein the antiprogestin is a progesterone receptor antagonist.

18. The kit of claim 14 wherein the agent expresses both androgenic and progestogenic activity.

19. The kit of claim 18 wherein the agent comprises the combination of an androgen and a progestin.

20. The kit of claim 18 wherein the agent is a single material which expresses both activities.

09313625-051899